TITLE

Medications for attention deficit hyperactivity disorder: cardiovascular concerns

AUTHOR(S)
Wooltorton, Eric
PUB. DATE
July 2006
SOURCE
CMAJ: Canadian Medical Association Journal;7/4/2006, Vol. 175 Issue 1, p29
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the advisory from Health Canada about a variety of stimulant and non-stimulant medications used to treat attention hyperactivity disorder (ADHD) which are linked to serious cardiovascular adverse events. Need for ADHD drugs to carry cautionary warnings; Cases of sudden death associated with the drug, according to a recent safety review of the U.S. Food and Drug Administration; Precautions for users of the drugs.
ACCESSION #
21376641

 

Related Articles

  • Pemoline (Cylert): market withdrawal. Hogan, Victoria // CMAJ: Canadian Medical Association Journal;1/11/2000, Vol. 162 Issue 1, p106 

    Reports the withdrawal of pemoline (Cylert) from the Canadian market on September 30, 1999. Therapeutic Products Programme of Health Canada conducting a benefit-risk assessment of the use of pemoline in the treatment of attention deficit hyperactivity disorder; Conclusion that the risk of liver...

  • ADHD drugs: update on psychiatric adverse events.  // Reactions Weekly;9/30/2006, Issue 1121, p2 

    The article reports on a revision made by Health Canada to the prescribing and patient information for medications used in the treatment of attention-deficit hyperactivity disorder (ADHD). The move focuses on incorporating information regarding possible psychiatric adverse events. ADHD drugs...

  • Amphetamine salts suspended.  // WHO Drug Information;2005, Vol. 19 Issue 1, p32 

    The article reports that Health Canada has suspended marketing of amphetamine salts for attention deficit hyperactivity disorder with effect February 9, 2005. The decision to withdraw amphetamine salts is founded on very rare, international, spontaneous reports of sudden deaths in paediatric and...

  • Health Canada suspends Adderall, US FDA advises caution.  // Reactions Weekly;2/19/2005, Issue 1039, p2 

    Reports on the move by Health Canada to suspend the market authorization of the Adderall drug, developed and manufactured by Shire BioChem Inc. Use of the drug for the treatment of attention-deficit hyperactivity disorder; Claims of sudden deaths, heart-related deaths and strokes in children...

  • AHRQ, FDA will examine ADHD drug cardiac risks.  // Cardiovascular Device Update;Oct2007, Vol. 13 Issue 10, p16 

    The article focuses on the collaboration of the Agency for Healthcare Research and Quality (AHRQ) and the U.S. Food and Drug Administration to study the potential for increased cardiovascular problems relating to the use of prescription drugs to treat attention deficit hyperactivity disorder...

  • Attention-Deficit/Hyperactivity Disorder, Stimulant Therapy, and the Patient with Congenital Heart Disease: Evidence and Reason. Batra, Anjan; Alexander, Mark; Silka, Michael // Pediatric Cardiology;Mar2012, Vol. 33 Issue 3, p394 

    Attention-deficit/hyperactivity disorder (ADHD) is the most common neurobehavioral disorder of childhood, and congenital heart disease (CHD) is the most common form of birth defect. Children with CHD are at increased risk for neurodevelopmental disorders such as ADHD. Stimulant medications,...

  • Sudden death and stimulant use in children with ADHD.  // Reactions Weekly;6/20/2009, Issue 1257, p3 

    The article focuses on a safety communication issued by the U.S. Food and Drug Administration regarding the use of stimulant medications for attention-deficit hyperactivity disorder (ADHD). The communication was issued following the publication of a study on the link between stimulant...

  • CARDIOVASCULAR RISK IN ADHD PHARMACOTHERAPY. HAMMERNESS, PAUL; TRAUM, AVRAM Z.; BECKER, JUDITH; DESHPANDE, ANITA // Contemporary Pediatrics;Nov2009, Vol. 26 Issue 11, p34 

    The article discusses various clinical cases demonstrating the cardiovascular risk associated with attention-deficit hyperactivity disorder (ADHD) pharmacotherapy. ADHD pharmacotherapy has been linked with cardiovascular events in children and adults. Symptoms that are commonly described are...

  • News Flash for People With ADHD. Shute, Nancy; McGrath, Anne // U.S. News & World Report;2/20/2006, Vol. 140 Issue 6, p65 

    This article focuses on a recommendation by the United States Food & Drug Administration (FDA) that Attention Deficit Hyperactivity Disorder (ADHD) drugs carry a warning that the drugs may cause cardiovascular problems. The recommendation was made after the FDA was alarmed by 25 sudden deaths in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics